
Abstract Abernethy malformation is a rare congenital vascular anomaly in which portal venous blood bypasses the liver and drains directly into the systemic circulation. As a result, splanchnic venous blood is not processed by the liver. Clinical manifestations include hyperammonemia causing hepatic encephalopathy, pulmonary arteriovenous malformations, primary pulmonary artery hypertension, and hepatic neoplasms. Herein, we describe the case of a three-year-old male with heterotaxy syndrome and complex congenital heart disease presenting for biventricular repair on cardiopulmonary bypass. He also had Abernethy malformation and a history of hepatic encephalopathy managed with intense medical therapy. Existing literature offers limited guidance on managing Abernethy malformation or hyperammonemia during cardiopulmonary bypass. We were concerned that the perioperative phase of surgery could acutely raise the ammonia to dangerous levels through blood transfusions and hemolysis due to prolonged time on the heart-lung machine and the excessive use of cardiotomy suction and vents using roller pumps. Therefore, a multidisciplinary team developed a comprehensive perioperative plan. This report describes careful monitoring and management across all perioperative phases, with an emphasis on cardiopulmonary bypass ammonia management through zero balanced ultrafiltration (Z-BUF). Together, these efforts contributed to a favorable postoperative outcome.
Background There is limited evidence on how long cardiopulmonary bypass (CPB) circuits can remain primed before use or when primed CPB circuits should be disposed of due to loss of sterility or instability of the priming solution. Understanding bacterial persistence in priming solutions is critical for patient safety and institutional protocols. This pilot study aimed to evaluate the survival of Staphylococcus epidermidis in Plasma-Lyte A-primed CPB circuits over time. Methods Three commercially available CPB circuits (Affinity, CAPIOX, and Inspire) from different manufacturers (Medtronic, Terumo, and LivaNova) were primed with Plasma-Lyte A inoculated with S. epidermidis (~1 CFU/mL) to simulate accidental contamination. Following brief recirculation, circuits were stored without circulation at 20–22°C. Samples were obtained aseptically from pre- and post-oxygenator sites on Days 0, 2, 4, 7, 9, and 11. Viable bacterial recovery was reported as colony-forming units per milliliter (CFU/mL) over time. Results Viable S. epidermidis was recovered from all three CPB circuits at both sampling sites through Day 11. Colony counts remained low, fluctuating between approximately 1 and 9 CFU/mL without a consistent increase over time. The highest observed count, 9 CFU/mL, occurred at the Inspire post-oxygenator sampling site on Day 7. Each measurement represented a single observation. Conclusion Viable S. epidermidis remained detectable at low levels in intentionally contaminated Plasma-Lyte A–primed CPB circuits over 11 days. These findings suggest that primed circuits may permit prolonged bacterial persistence, raising concerns about potential patient exposure if contaminated circuits are used. This pilot study reinforces the importance of strict aseptic technique, careful consideration of storage duration, and appropriate institutional protocols for circuit management and microbial monitoring. Thesefindings may inform handling of preassembled, customized circuits tailored to institutional needs. Larger, replicated studies with appropriate controls are needed to characterize bacterial persistence and establish evidence-based guidance for primed circuit storage.
Background: Temporary right ventricular assist device (RVAD) support is used during selected high-risk cardiac operations, including durable left ventricular assist device implantation, orthotopic heart transplantation, and procedures complicated by anticipated right ventricular failure. When RVAD implantation is planned during cardiopulmonary bypass (CPB), the RVAD circuit is commonly primed with crystalloid solution. Although 500-600 mL may appear modest in many adult patients, this secondary circuit prime may produce clinically meaningful hemodilution in patients who are frequently anemic, volume loaded, and near transfusion thresholds, where relatively small changes in hematocrit may alter clinical management. Technique: This report describes an autologous priming technique that uses patient blood available during CPB to displace crystalloid from the RVAD circuit before completion of the outflow connection. The technique requires no change to the conventional RVAD circuit, adds minimal time, and can be discontinued at any point if patient conditions do not safely permit further displacement. Discussion: This technique applies established autologous priming principles to a secondary extracorporeal circuit introduced after CPB has already been established. The objective is to avoid an unnecessary crystalloid load, minimize secondary hemodilution, and preserve hematocrit at the margin where transfusion decisions are commonly made. Conclusion: Autologous priming of the RVAD circuit during planned implantation is a simple, reproducible, patient-directed technique for minimizing secondary hemodilution while preserving conventional RVAD deployment.